Studies suggest that plasma IL-17 levels may serve as a biomarker to distinguish AD patients from cognitively healthy individuals, and that cerebrospinal fluid IL-17 levels may help identify tau pathology in frontotemporal dementia (FTD) [100,101]. The gene discussed is MAPT; the disease is frontotemporal dementia.